Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sharpless Calls For A Nimble, Flexible, More Efficient US FDA

Executive Summary

In his first speech to an outside group, Sharpless strikes a collaborative tone, saying he expects to listen to the advice of the FDA bar, as well as his own experts.

You may also be interested in...



Stephen Hahn For US FDA Commissioner: Will Academic Experience Suffice For Confirmation?

The MD Anderson Cancer Center administrator's lack of significant government administration experience may inspire questions during the confirmation process.

“Nobody Was Armed At NCI”: US FDA Head Sharpless Adjusts To Life As Regulator

Acting commissioner is entering the usual learning curve for new leaders of the agency. It’s a reminder of how unusual it was to skip that step under his predecessor.

Vocabulary Change: CDER Eliminating 'Review' For NDAs And BLAs

Like ANDA evaluations, US FDA plans to use the word assessment to describe them for NDAs and BLAs.

Related Content

Topics

UsernamePublicRestriction

Register

MT142578

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel